Abstract
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
Publication types
-
Introductory Journal Article
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Antibodies, Blocking / immunology*
-
Antibodies, Monoclonal / immunology*
-
CD8-Positive T-Lymphocytes / immunology*
-
CTLA-4 Antigen / antagonists & inhibitors*
-
CTLA-4 Antigen / immunology*
-
Female
-
Humans
-
Neoplasms / immunology*
-
Neoplasms / pathology*
Substances
-
Antibodies, Blocking
-
Antibodies, Monoclonal
-
CTLA-4 Antigen